Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
boston blog main
drugs
5
×
life sciences
national blog main
boston
boston top stories
clinical trials
rna interference
fda
new york blog main
new york top stories
patisiran
akcea therapeutics
aminolevulinic acid
biotech
givosiran
hereditary transthyretin amyloidosis
inotersen
national top stories
onpattro
regeneron pharmaceuticals
san diego blog main
san diego top stories
tafamidis
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
alirocumab
amgen
barry greene
boston university
dan ollendorf
european medicines agency
evercore isi
evolocumab
harvard pilgrim health care
heart attack
inclisiran
What
alnylam
5
×
rna
5
×
drug
medicine
fda
interference
pharmaceuticals
rnai
ago
data
new
second
seek
speedy
uses
approval
approve
approves
awaits
based
biological
cells
cholesterol
cleared
crossed
decades
decision
discovered
ema
employ
europe
evidence
far
fingers
follows
friday
gene
harmful
heart
historic
Language
Current search:
rna
×
drugs
×
alnylam
×
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision